研发支出 - Akari Therapeutics 报告了截至2024年3月31日的第一季度财务状况，现金约为130万美元[7] - 研发支出为2024年第一季度约为230万美元，较2023年同期的约170万美元增加[8] - Akari Therapeutics Plc 2024年第一季度研发支出为2,279,000美元，较去年同期增长31%[30] 其他收入 - 总的其他收入净额为2024年第一季度约为400万美元，较2023年同期的约560万美元减少[10] 净亏损 - 净亏损为2024年第一季度约为560万美元，较2023年同期的约100万美元净收入减少[12] - Akari Therapeutics Plc 2024年第一季度总体亏损为5,566,000美元，较去年同期亏损额增加457%[30] 现金余额 - Akari Therapeutics Plc 2024年第一季度现金余额为1,310,000美元，较去年同期减少66%[30]

Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024 Samir R. Patel, M.D. Appointed Interim CEO Plan for Prioritization of Peak Bio's ADC Cancer Therapeutic Platform Technology and Akari's PAS-nomacopan for Geographic Atrophy Implementation of Restructuring Plan to Reduce Operating Costs Existing Investors Support the Company with Issuance of $1 million in Unsecured Convertible Notes BOSTON and LONDON, May 16, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number 001-36288 Akari Therapeutics, Plc (Exact name of Registrant as specified in its Charter) England and Wales ...

BOSTON and LONDON, April 15, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the company will present new pre-clinical data on investigational long-acting PAS-nomacopan including drug effect on electroretinography (ERG) testing in a blue light model at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting in Seattle. Akari Chief Scientific Off ...

BOSTON and LONDON, April 15, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the company will present new pre-clinical data on investigational long-acting PAS-nomacopan including drug effect on electroretinography (ERG) testing in a blue light model at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting in Seattle. Akari Chief Scientific Of ...

Exhibit 99.1 Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights BOSTON and LONDON, April 1, 2024 (GLOBE NEWSWIRE) – Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported financial results for the full year 2023 as well as recent company highlights. “Amidst challenging economic conditions during 2023 in the biotech sector and beyond, the Akari team advanced our Phase 3 and ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number 001-36288 Akari Therapeutics, Plc (Exact name of Registrant as specified in its Charter) England and Wales 98-1 ...

Kuehn Law调查 - Kuehn Law正在调查多家公司的潜在合并事宜[1] Vivakor与Empire Diversified Energy合并 - Vivakor已同意与Empire Diversified Energy合并，交易条款包括Vivakor将以67,200,000股Vivakor普通股的净考虑价值收购Empire的所有流通股和优先股[2] Hess Corporation被Chevron收购 - Hess Corporation同意被Chevron收购，Hess股东将获得每股1.0250股Chevron普通股[3] Superior Drilling被Drilling Tools International收购 - Superior Drilling同意被Drilling Tools International收购，Superior Drilling将获得约32.2百万美元的现金和股票[4]

Exhibit 99.1 AKARI THERAPEUTICS, PLC For The Six Month Period Ended June 30, 2023 TABLE OF CONTENTS Condensed Consolidated Financial Statements (Unaudited) Page Condensed Consolidated Balance Sheets as of June 30, 2023 and December 31, 2022 2 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Six Months Ended June 30, 2023 and 2022 3 Condensed Consolidated Statements of Changes in Shareholders’ Equity for the Six Months Ended June 30, 2023 and 2022 4 Condensed Consolidated Statem ...

公司财务状况 - 公司历史上存在经营亏损，未来收入或运营利润无法保证；投资者可能会损失全部投资[17] - 公司截至2022年12月31日现金约为1320万美元，公司认为没有足够资金来支持未来12个月的运营[44] - 公司可能需要筹集额外资金，可能通过发行股票、可转换证券或其他股权证券来实现，这可能会导致现有股东持股比例显著稀释[49] - 公司的ADS可能会被纳斯达克资本市场强制摘牌，如果未能遵守持续上市要求[111] 产品开发与商业化 - 公司的业务成功与否取决于nomacopan的成功，如果无法获得nomacopan的营销授权或成功商业化，公司的业务可能会受到重大影响[50] - 公司可能会遇到招募患者参与临床试验的困难，这可能会导致临床开发活动延迟或受到不利影响[52] - 公司可能会遇到临床试验或nomacopan的营销授权流程延长、延迟或暂停的情况，这可能会导致无法及时商业化nomacopan[55] - 公司可能无法获得nomacopan用于HSCT-TMA治疗的优先审查券，这可能会影响未来产品的优先审查[58] 风险因素 - 公司可能会遇到产品责任诉讼风险，可能导致巨额责任和限制任何已批准产品的商业化[85] - 公司的业务和运营可能会受到计算机系统故障或安全漏洞的影响[89] - 公司或我们依赖的第三方可能会受到自然灾害和/或健康流行病的不利影响[91] - 公共卫生大流行、流行病或爆发可能对我们的业务产生不利影响[92] 法律与知识产权 - 公司成功依赖于保护知识产权和专有技术[74] - 公司专利的有效期望在2024年至2035年之间[74] - 公司可能因专利侵权或其他知识产权违规而被迫停止商业化产品[78] 市场与经济环境 - 未来产品的市场接受度和市场规模可能影响公司的收入[82] - 全球经济状况不确定或持续波动可能对公司的业务、运营结果和财务状况产生重大不利影响[112] - 通货膨胀、COVID-19复苏、地缘政治事件和全球供应链中断等因素可能导致全球经济不确定性增加，对公司融资造成困难[113] 产品信息与临床试验 - 公司的主导产品候选人nomacopan是一种来源于蜱虫唾液的重组小蛋白，具有双重抑制作用，已获得美国FDA和欧洲EMA的孤儿药物认定[139] - 公司进行了多项临床试验，包括针对HSCT-TMA的关键试验，该疾病目前在美国和欧洲尚无批准的治疗方案[141] - nomacopan在儿童HSCT-TMA患者中的临床病例研究表明治疗效果良好，无与nomacopan相关的不良事件[144] 法规与市场准入 - FDA对新药进行批准前需要通过新药申请(NDA)流程[171] - 孤儿药品指定可使产品获得七年的独家销售权[183] - 欧盟市场授权程序包括集中授权程序、相互认可程序、分散程序和国家程序[191] - 英国自2021年1月1日起不再直接适用欧盟法律，已采纳现有的欧盟药品法规作为独立的英国立法[201]